Phaleria macrocarpa extract

Drug Profile

Phaleria macrocarpa extract

Alternative Names: DLBS 1425; Phalecarps

Latest Information Update: 07 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dexa Medica
  • Class Antineoplastics; Phytotherapies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis stimulants; Caspase stimulants; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 30 Nov 2012 Dexa Medica Group completes a phase II/III trial in Breast cancer (neoadjuvant therapy) in Indonesia (NCT01433562)
  • 10 Oct 2012 Dexa Medica Group terminates a phase II trial for Breast cancer in Indonesia (NCT01006785)
  • 08 Apr 2012 Dexa Medica Group initiates enrolment in a phase II trial for Breast cancer in Indonesia (NCT01006785)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top